JonesTrading Thinks Deciphera Pharmaceuticals Inc’s Stock is Going to Recover

By Carrie Williams

JonesTrading analyst Soumit Roy maintained a Buy rating on Deciphera Pharmaceuticals Inc (DCPHResearch Report) on May 10 and set a price target of $65. The company’s shares closed on Friday at $23.01, close to its 52-week low of $18.55.

According to, Roy has currently no stars on a ranking scale of 0-5 stars, with an average return of -14.2% and a 27.8% success rate. Roy covers the Healthcare sector, focusing on stocks such as Neon Therapeutics Inc, Vascular Biogenics, and Infinity Pharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Deciphera Pharmaceuticals Inc with a $55 average price target.

See today’s analyst top recommended stocks >>

Based on Deciphera Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $32.3 million. In comparison, last year the company had a GAAP net loss of $21.43 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DCPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.